PROPHASE LABS INC (PRPH) Stock Price & Overview

NASDAQ:PRPH • US74345W1080

Current stock price

0.3626 USD
-0.08 (-18.97%)
At close:
0.1814 USD
-0.18 (-49.97%)
After Hours:

The current stock price of PRPH is 0.3626 USD. Today PRPH is down by -18.97%. In the past month the price decreased by -73.2%. In the past year, price decreased by -95.64%.

PRPH Key Statistics

52-Week Range0.3 - 8.5
Current PRPH stock price positioned within its 52-week range.
1-Month Range0.3 - 1.839
Current PRPH stock price positioned within its 1-month range.
Market Cap
15.947M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-23.40
Dividend Yield
N/A

PRPH Stock Performance

Today
-18.97%
1 Week
-41.04%
1 Month
-73.20%
3 Months
-93.52%
Longer-term
6 Months -91.34%
1 Year -95.64%
2 Years -99.25%
3 Years -99.56%
5 Years -99.64%
10 Years -97.03%

PRPH Stock Chart

PROPHASE LABS INC / PRPH Daily stock chart

PRPH Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to PRPH. When comparing the yearly performance of all stocks, PRPH is a bad performer in the overall market: 99.84% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PRPH Earnings

Next Earnings DateMar 30, 2026
Last Earnings DateNov 17, 2025
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise -84.79%

PRPH Forecast & Estimates

For the next year, analysts expect an EPS growth of 97.56% and a revenue growth 64.06% for PRPH


Analysts
Analysts82.86
Price TargetN/A
EPS Next Y97.56%
Revenue Next Year64.06%

PRPH Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

PRPH Financial Highlights

Over the last trailing twelve months PRPH reported a non-GAAP Earnings per Share(EPS) of -23.4. The EPS decreased by -138.78% compared to the year before.


Income Statements
Revenue(TTM)6.77M
Net Income(TTM)-53.36M
Industry RankSector Rank
PM (TTM) N/A
ROA -81.22%
ROE -777.79%
Debt/Equity 0.74
Chartmill High Growth Momentum
EPS Q2Q%52.33%
Sales Q2Q%-71.93%
EPS 1Y (TTM)-138.78%
Revenue 1Y (TTM)-80.65%

PRPH Ownership

Ownership
Inst Owners5.25%
Shares43.98M
Float40.66M
Ins Owners5.75%
Short Float %0.17%
Short Ratio0.01

About PRPH

Company Profile

PRPH logo image ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 96 full-time employees. The firm is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. The company develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The firm also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.

Company Info

IPO: 1984-01-16

PROPHASE LABS INC

711 Stewart Ave, Suite 200, Garden City

New York City NEW YORK 11530 US

CEO: Ted Karkus

Employees: 96

PRPH Company Website

PRPH Investor Relations

Phone: 12153450919

PROPHASE LABS INC / PRPH FAQ

What does PROPHASE LABS INC do?

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 96 full-time employees. The firm is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. The company develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The firm also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.


Can you provide the latest stock price for PROPHASE LABS INC?

The current stock price of PRPH is 0.3626 USD. The price decreased by -18.97% in the last trading session.


Does PRPH stock pay dividends?

PRPH does not pay a dividend.


What is the ChartMill technical and fundamental rating of PRPH stock?

PRPH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What sector and industry does PROPHASE LABS INC belong to?

PROPHASE LABS INC (PRPH) operates in the Health Care sector and the Pharmaceuticals industry.


Is PROPHASE LABS INC (PRPH) expected to grow?

The Revenue of PROPHASE LABS INC (PRPH) is expected to grow by 64.06% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the upcoming earnings date for PROPHASE LABS INC?

PROPHASE LABS INC (PRPH) will report earnings on 2026-03-30, after the market close.